GSK Past Earnings Performance
Past criteria checks 0/6
GSK's earnings have been declining at an average annual rate of -5.2%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been declining at an average rate of 1.8% per year. GSK's return on equity is 21.2%, and it has net margins of 8%.
Key information
-5.2%
Earnings growth rate
-5.8%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | -1.8% |
Return on equity | 21.2% |
Net Margin | 8.0% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How GSK makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 31,311 | 2,511 | 10,839 | 6,042 |
30 Jun 24 | 31,446 | 4,033 | 9,284 | 6,049 |
31 Mar 24 | 30,740 | 4,484 | 9,070 | 5,956 |
31 Dec 23 | 30,328 | 4,928 | 9,156 | 5,823 |
30 Sep 23 | 29,652 | 6,078 | 8,965 | 5,580 |
30 Jun 23 | 29,334 | 5,373 | 8,767 | 5,436 |
31 Mar 23 | 29,085 | 4,455 | 8,460 | 5,282 |
31 Dec 22 | 29,324 | 4,461 | 8,179 | 5,153 |
30 Sep 22 | 29,024 | 3,387 | 7,803 | 4,905 |
30 Jun 22 | 27,822 | 3,505 | 7,429 | 4,741 |
31 Mar 22 | 26,731 | 4,013 | 7,104 | 4,691 |
31 Dec 21 | 24,696 | 3,316 | 6,784 | 4,627 |
30 Sep 21 | 26,359 | 3,567 | 7,436 | 4,640 |
30 Jun 21 | 28,378 | 3,934 | 8,285 | 4,566 |
31 Mar 21 | 30,164 | 4,983 | 9,176 | 4,622 |
31 Dec 20 | 24,354 | 4,873 | 7,041 | 4,397 |
30 Sep 20 | 34,259 | 6,371 | 10,719 | 4,537 |
30 Jun 20 | 34,998 | 6,679 | 11,085 | 4,648 |
31 Mar 20 | 35,183 | 5,380 | 10,993 | 4,519 |
31 Dec 19 | 33,754 | 4,645 | 10,962 | 4,405 |
30 Sep 19 | 33,052 | 4,561 | 10,103 | 4,266 |
30 Jun 19 | 31,759 | 4,427 | 9,575 | 4,065 |
31 Mar 19 | 31,260 | 3,904 | 9,488 | 3,887 |
31 Dec 18 | 30,821 | 3,623 | 9,500 | 3,799 |
30 Sep 18 | 30,263 | 1,862 | 9,234 | 3,755 |
30 Jun 18 | 30,014 | 1,656 | 9,185 | 3,696 |
31 Mar 18 | 30,024 | 1,035 | 9,143 | 3,890 |
31 Dec 17 | 30,186 | 1,532 | 9,424 | 3,925 |
30 Sep 17 | 30,133 | 2,335 | 9,303 | 3,886 |
30 Jun 17 | 29,832 | 1,931 | 9,260 | 3,863 |
31 Mar 17 | 29,044 | 1,676 | 9,017 | 3,604 |
31 Dec 16 | 27,889 | 912 | 8,852 | 3,550 |
30 Sep 16 | 26,589 | 301 | 8,553 | 3,370 |
30 Jun 16 | 25,174 | 31 | 8,025 | 3,226 |
31 Mar 16 | 24,530 | 615 | 8,097 | 3,163 |
31 Dec 15 | 23,923 | 8,422 | 9,232 | 3,560 |
30 Sep 15 | 23,823 | 9,809 | 7,810 | 3,218 |
30 Jun 15 | 23,342 | 9,672 | 7,425 | 3,227 |
31 Mar 15 | 23,015 | 10,177 | 7,261 | 3,258 |
31 Dec 14 | 23,006 | 2,756 | 8,246 | 3,450 |
30 Sep 14 | 23,726 | 4,184 | 7,209 | 3,333 |
30 Jun 14 | 24,590 | 4,752 | 7,673 | 3,359 |
31 Mar 14 | 25,647 | 5,143 | 7,820 | 3,478 |
31 Dec 13 | 26,505 | 5,436 | 8,480 | 3,923 |
Quality Earnings: GS71 has a large one-off loss of £3.0B impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: GS71's current net profit margins (8%) are lower than last year (20.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GS71's earnings have declined by 5.2% per year over the past 5 years.
Accelerating Growth: GS71's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: GS71 had negative earnings growth (-58.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (25.4%).
Return on Equity
High ROE: Whilst GS71's Return on Equity (21.17%) is high, this metric is skewed due to their high level of debt.